CAMBRIDGE, Mass. (TheStreet) --An oral cancer drug from Ariad Pharmaceuticals (ARIA) helped patients with soft tissue and bone cancer remain in remission longer than a placebo, according to results from a phase III study released Tuesday.
The Ariad drug, ridaforolimus, is being jointly developed by Merck (MRK), which plans to file for approval later this year based on positive data from Tuesday's study.
The "Succeed" study enrolled 711 patients with soft-tissue or bone sarcoma who responded to previous treatment with chemotherapy. Patients were then treated with daily ridaforolimus or a placebo to determine whether the former could extend the time before the patients' tumors started to grow again.
Based on a full, independent analysis of the study, patients treated with ridaforolimus reported a 28% reduction in risk of cancer progression compared to patients treated with a placebo. The result was highly statistically significant, achieving the primary endpoint of the study.At the median, ridaforolimus' benefit was more modest, demonstrating a 3.1-week benefit in progression-free survival over placebo (17.7 weeks compared to 14.6 weeks.) The most common side effects of ridaforolimus observed in the study stomatitis (mouth sores), fatigue, diarrhea and thrombocytopenia. Patients in the study are still be followed to determine, in part, whether ridaforolimus can help sarcoma patients live longer. The study was conducted under a Special Protocol Agreement with FDA that allows the company to seek approval based on the positive disease-progression endpoint. Ariad shares were up 36% to $7.16 in pre-market trading. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV